网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
幽门螺杆菌感染患者CYP2C19基因多态性分析
作者:刘振宇1  邹傲2  邹兵2  杨莉丽2  郭海2  刘永革2  王俊萍2 
单位:1. 深圳大学总医院 消化内科, 广东 深圳 518055;
2. 北京大学深圳医院 消化内科, 广东 深圳 518036
关键词:幽门螺杆菌 质子泵抑制剂 基因多态性 CYP2C19基因 
分类号:R570.32;R378.3
出版年·卷·期(页码):2019·38·第十一期(1344-1347)
摘要:

目的:探讨深圳市幽门螺杆菌感染患者细胞色素P450 2C19(CYP2C19)基因多态性的分布频率,提高该地区幽门螺杆菌的清除率。方法:采用多重PCR及可视化基因芯片技术对244例初诊于北京大学深圳医院的幽门螺杆菌感染患者的胃黏膜组织进行检测,测定内容为组织标本中人细胞色素P450与质子泵抑制剂代谢相关的等位基因2C19*2、2C19*3突变位点,检测结果根据药物代谢活性分为强代谢型、中代谢型和弱代谢型。结果:本研究共检测到CYP2C19强代谢型患者占39.7%(97例),中代谢型患者占57.7%(141例),弱代谢型患者占1.6%(4例),未检出的患者占0.8%(2例)。通过χ2检验发现,不同年龄及性别的患者其CYP2C19的代谢型差异无统计学意义(P>0.05)。结论:北京大学深圳医院就诊的幽门螺杆菌感染患者中CYP2C19的代谢型以强代谢型和中代谢型为主,在行幽门螺杆菌根除治疗的过程中要注意个体差异及精准化治疗。

Objective: To explore the distribution of CYP2C19 genetic polymorphisms in patients with Helicobacter Pylori (H. Pylori) in Shenzhen City, Guangdong Province to improve the H. Pylori eradication rate in the area. Methods: In this study, multiple PCR and visual gene chip techniques were used to detect the gastric mucosa of 244 patients with H. Pylori infection in Shenzhen Hospital of Peking University. The mutation sites of 2C19*2 and 2C19*3, which were related to human cytochrome P450 and proton pump inhibitor metabolism, were detected. According to the drug metabolic activity, the results were divided into strong metabolic type, middle metabolic type and weak metabolic type. Results: A total of 39.7% (97 cases) of CYP2C19 patients with strong metabolic type, 57.7% (141 cases) with moderate metabolic type, 1.6% (4 cases) with weak metabolic type and 0.8% (2 cases) without detection were detected in this study. There was no significant difference in the metabolic type of CYP2C19 among patients of different ages and genders(P>0.05).Conclusion: The metabolic type of CYP2C19 in patients with H. Pylori infection in Shenzhen Hospital of Peking University is mainly strong metabolic type and moderate metabolic type. Attention should be paid to individual differences and accurate treatment in the process of H. Pylori eradication.

参考文献:

[1] ZHOU S F, LIU J P, CHOWBAY B. Polymorphism of human cytochrome P450 enzymes and its clinical impact[J]. Drug Metab Rev, 2009,41(2):89-95.
[2] STROM C M, GOOS D, CROSSLEY B, et al. Testing for variants in CYP2C19:population frequencies and testing experience in a clinical laboratory[J]. Genet Med, 2012, 14(1):95-100.
[3] OWUSU OBENG A, EGELUND E F, ALSULTAN A, et al. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole:are we ready for clinical implementation of pharmacogenomics[J]. Pharmacotherapy, 2014,34(7):703-718.
[4] 刘文忠, 谢勇, 陆红,等. 第五次全国幽门螺旋杆菌感染处理共识报告[J]. 中国实用内科杂志,2017,37(6):509-524.
[5] LEJA M, AXON A, BRENNER H. Epidemiology of Helicobacter pylori infection[J]. Helicobacter,2016,21(Suppl 1):3-7.
[6] SONNENBERG A, LASH R H, GENTA R M. A national study of Helicobactor pylori infection in gastric biopsy specimens[J]. Gastroenterology, 2010,139(6):1894-1901.
[7] 缪亚军,杨莉. 紫杉醇联合顺铂调控MAPK/NF-κB信号治疗幽门螺杆菌胃癌机制的研究[J].东南大学学报(医学版),2018,37(4):706-710.
[8] SUGANO K, TACK J, KUIPERS E J, et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut, 2015,64(9):1353-1367.
[9] DELLA MONICA P, LAVAGNA A, MASOERO G, et al. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy[J]. Aliment Pharmacol Ther, 2002,16(6):1269-1275.
[10] KUO C H, KUO F C, HU H M, et al. The optimal first-line therapy of Helicobacter pylori infection in year 2012[J]. Gastroenterol Res Pract,2012,17(3):357-361.
[11] GISBERT J P. Potent gastric acid inhibition in Helicobacter pylori eradication[J]. Drugs,2005,65(10):83-96.
[12] 李晓敏, 余霞霞. 合理用药干预对外科预防性使用质子泵抑制剂的影响[J].东南大学学报(医学版), 2019,38(1):43-46.
[13] GOLDSTEIN J A, ISHIZAKI T, CHIBA K, et al. Frequencies of the detective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations[J]. Pharmacogenetics,1997,16(7):59-64.
[14] IEIRI I, KUBOTA T, URAE A, et al. Pharmacokinetics of omeprazole (a subject of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects[J]. Clin Pharmacol Ther,1996,59(11):647-653.
[15] YAMADA S, ONDA M, KATO S, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations[J]. J Gastroenterol, 2001, 36(10):669-672.
[16] 周健, 吕虹, 康熙雄. 中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶CYP2C19基因多态性的检测[J]. 中国临床药理学与治疗学, 2007,12(2):208-213.
[17] 蒋兴然, 张云岗, 路军, 等.北方地区汉族消化道疾病中CYP2C19基因多态性分析[J]. 临床与实验病理学杂志, 2016,32(10):1101-1109.
[18] 李传保, 戴大鹏, 蔡杰, 等.中国汉族人群24种CYP2C19新突变体的体外活性研究[J]. 山西医科大学学报, 2015,46(5):428-433.
[19] SUGIMOTO M, UOTANI T, SAHARA S, et al. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion[J]. Helicobacter,2014,19(10):312-318.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 299319 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541